Logo image of SONN

SONNET BIOTHERAPEUTICS HOLDI (SONN) Stock Price, Quote, News and Overview

NASDAQ:SONN - Nasdaq - US83548R4020 - Common Stock - Currency: USD

1.44  +0.01 (+0.7%)

SONN Quote, Performance and Key Statistics

SONNET BIOTHERAPEUTICS HOLDI

NASDAQ:SONN (2/21/2025, 8:00:02 PM)

1.44

+0.01 (+0.7%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High18.72
52 Week Low1.38
Market Cap4.39M
Shares3.05M
Float3.00M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)05-12 2025-05-12
IPO07-27 2005-07-27


SONN short term performance overview.The bars show the price performance of SONN in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -20 -40 -60

SONN long term performance overview.The bars show the price performance of SONN in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of SONN is 1.44 USD. In the past month the price decreased by -15.79%. In the past year, price decreased by -89.83%.

SONNET BIOTHERAPEUTICS HOLDI / SONN Daily stock chart

SONN Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.97 357.10B
AMGN AMGEN INC 15.29 162.72B
GILD GILEAD SCIENCES INC 23.85 137.00B
VRTX VERTEX PHARMACEUTICALS INC 1669.79 124.40B
REGN REGENERON PHARMACEUTICALS 15.34 76.56B
ARGX ARGENX SE - ADR N/A 39.16B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 32.32B
BNTX BIONTECH SE-ADR N/A 28.77B
ONC BEIGENE LTD-ADR N/A 27.25B
NTRA NATERA INC N/A 21.43B
BIIB BIOGEN INC 8.54 20.49B
SMMT SUMMIT THERAPEUTICS INC N/A 16.31B

About SONN

Company Profile

SONN logo image Sonnet Biotherapeutics Holdings Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Princeton, New Jersey and currently employs 12 full-time employees. The company went IPO on 2005-07-27. Sonnet BioTherapeutics Holdings, Inc. is a clinical-stage, oncology-focused biotechnology company with a proprietary platform for biologic medicines of single-or bifunctional action. Its technology, namely Fully Human Albumin Binding (FHAB), utilizes a fully human single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. The company designed the FHAB construct to improve drug accumulation in tumors, and to extend the duration of activity in the body. Its lead asset, SON-1010, is a fully human single-chain version of Interleukin 12, covalently linked to the FHAB construct, for which it is pursuing clinical development in solid tumors. Its lead clinical stage asset, SON-080, is the native human version of IL-6 that is manufactured in Chinese Hamster Ovary cells. SON-080, for its target indications of Chemotherapy-Induced Peripheral Neuropathy and Diabetic Peripheral Neuropathy. Its pipeline also includes SON-1210, SON-1410 and SON-3015.

Company Info

SONNET BIOTHERAPEUTICS HOLDI

100 Overlook Center, Suite 102

Princeton NEW JERSEY 08540 US

CEO: Pankaj Mohan

Employees: 12

Company Website: https://www.sonnetbio.com/

Investor Relations: http://www.sonnetbio.com/investors

Phone: 16093752227

SONNET BIOTHERAPEUTICS HOLDI / SONN FAQ

What is the stock price of SONNET BIOTHERAPEUTICS HOLDI today?

The current stock price of SONN is 1.44 USD. The price increased by 0.7% in the last trading session.


What is the ticker symbol for SONNET BIOTHERAPEUTICS HOLDI stock?

The exchange symbol of SONNET BIOTHERAPEUTICS HOLDI is SONN and it is listed on the Nasdaq exchange.


On which exchange is SONN stock listed?

SONN stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for SONNET BIOTHERAPEUTICS HOLDI stock?

7 analysts have analysed SONN and the average price target is 20.4 USD. This implies a price increase of 1316.67% is expected in the next year compared to the current price of 1.44. Check the SONNET BIOTHERAPEUTICS HOLDI stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is SONNET BIOTHERAPEUTICS HOLDI worth?

SONNET BIOTHERAPEUTICS HOLDI (SONN) has a market capitalization of 4.39M USD. This makes SONN a Nano Cap stock.


How many employees does SONNET BIOTHERAPEUTICS HOLDI have?

SONNET BIOTHERAPEUTICS HOLDI (SONN) currently has 12 employees.


What are the support and resistance levels for SONNET BIOTHERAPEUTICS HOLDI (SONN) stock?

SONNET BIOTHERAPEUTICS HOLDI (SONN) has a resistance level at 1.6. Check the full technical report for a detailed analysis of SONN support and resistance levels.


Should I buy SONNET BIOTHERAPEUTICS HOLDI (SONN) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does SONNET BIOTHERAPEUTICS HOLDI (SONN) stock pay dividends?

SONN does not pay a dividend.


When does SONNET BIOTHERAPEUTICS HOLDI (SONN) report earnings?

SONNET BIOTHERAPEUTICS HOLDI (SONN) will report earnings on 2025-05-12.


What is the Price/Earnings (PE) ratio of SONNET BIOTHERAPEUTICS HOLDI (SONN)?

SONNET BIOTHERAPEUTICS HOLDI (SONN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-10.43).


What is the Short Interest ratio of SONNET BIOTHERAPEUTICS HOLDI (SONN) stock?

The outstanding short interest for SONNET BIOTHERAPEUTICS HOLDI (SONN) is 3.85% of its float. Check the ownership tab for more information on the SONN short interest.


SONN Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

SONN Financial Highlights

Over the last trailing twelve months SONN reported a non-GAAP Earnings per Share(EPS) of -10.43. The EPS increased by 89.77% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -268.39%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%37.1%
Sales Q2Q%5267.69%
EPS 1Y (TTM)89.77%
Revenue 1Y (TTM)-87.4%

SONN Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 83% to SONN. The Buy consensus is the average rating of analysts ratings from 7 analysts.


Ownership
Inst Owners3.06%
Ins Owners1.54%
Short Float %3.85%
Short Ratio0.09
Analysts
Analysts82.86
Price Target20.4 (1316.67%)
EPS Next Y69.27%
Revenue Next YearN/A